COG ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-high-risk Neuroblastoma

Objective

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.

https://clinicaltrials.gov/ct2/show/NCT02176967

Location: Essentia Health Cancer Centers

Research Study Categories

  • Pediatric Studies

Specialty

  • Rare Tumor
Contact
Cancer Clinical Trials at 844-681-7944
or cancertrials@essentiahelath.org

Like most websites, we use cookies and other technologies to keep our website reliable, secure, and to better understand how our site is used. By using our site, you agree to our use of these tools. Learn more.